ReviewNephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association2018
Membrane innovation: closer to native kidneys.
Review in Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- Performance-based classification of dialyzers: integrating YKL-40 for advanced middle-molecule clearance - A Chinese expert consensus.Renal failure · 2026Review
- Advances in Membrane, Dialyzer Design, and Related Monitoring Technologies for Hemodiafiltration: Translating Bench-Side Innovations to Bedside Applications.Journal of clinical medicine · 2026Review
- Article
- Increasing the Removal of Large Solutes by Kidney Replacement Therapy.Journal of the American Society of Nephrology : JASN · 2025Review
- Current dialyzer classification in Japan and mortality risk in patients undergoing hemodialysis.Scientific reports · 2024Article
- Investigation of the inhibition of bacteria and endotoxin influx by back filtration through dialyzer membranes.Journal of artificial organs : the official journal of the Japanese Society for Artificial Organs · 2024Article
- Middle Molecular Uremic Toxin and Blood Purification Therapy.Journal of clinical medicine · 2024Review
- Portable, wearable and implantable artificial kidney systems: needs, opportunities and challenges.Nature reviews. Nephrology · 2023Review
- Expanded hemodialysis: what's up, Doc?Clinical kidney journal · 2023Review
- Expanded Hemodialysis ameliorates uremia-induced impairment of vasculoprotective KLF2 and concomitant proinflammatory priming of endothelial cells through an ERK/AP1/cFOS-dependent mechanism.Frontiers in immunology · 2023Article
- Effects of Expanded Hemodialysis with Medium Cut-Off Membranes on Maintenance Hemodialysis Patients: A Review.Membranes · 2022Review
- The scientific principles and technological determinants of haemodialysis membranes.Clinical kidney journal · 2021Review
- Choices in hemodialysis therapies: variants, personalized therapy and application of evidence-based medicine.Clinical kidney journal · 2021Review
- Changes in practice patterns in Japan from before to after JSDT 2013 guidelines on hemodialysis prescriptions: results from the JDOPPS.BMC nephrology · 2021Article
- A Review of Commercial Developments and Recent Laboratory Research of Dialyzers and Membranes for Hemodialysis Application.Membranes · 2021Review
- Characterization of the cylindrical electrospun nanofibrous polysulfone membrane for hemodialysis with modelling approach.Medical & biological engineering & computing · 2021Article
- Expanded Hemodialysis Therapy Ameliorates Uremia-Induced Systemic Microinflammation and Endothelial Dysfunction by Modulating VEGF, TNF-α and AP-1 Signaling.Frontiers in immunology · 2021Article
- Dialyzer Classification and Mortality in Hemodialysis Patients: A 3-Year Nationwide Cohort Study.Frontiers in medicine · 2021Article
- Innovations in dialysis membranes for improved kidney replacement therapy.Nature reviews. Nephrology · 2020Article
- OxonePolymers · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Modern methods in analytical biochemistry have established that uraemia is associated with the retention of proteins, both in their native state and post-translationally modified, over a wide range of molecular weights up to 60 kDa. Evidence is accumulating that these higher molecular weight retention solutes are important uraemic toxins, and therapies such as online haemodiafiltration (HDF), which enhance their removal, are associated with improved outcomes. However, HDF has limitations regarding cost, clinical implementation and the need for an external source of sterile substitution solution to maintain fluid balance. New membranes that have a solute removal profile more closely approaching that of the glomerular filtration barrier when used for conventional haemodialysis, while at the same time not allowing the passage of clinically significant amounts of beneficial proteins, are needed to address these limitations. Tighter control of the molecular characteristics of the polymers used for membrane fabrication, along with the introduction of additives and improvements in the manufacturing process, has led to membranes with a tighter pore size distribution that allows the use of an increased absolute pore size without leaking substantial amounts of albumin. At the same time, the wall thickness and internal diameter of membrane fibres have been decreased, enhancing convective transport within the dialyser without the need for an external source of substitution solution. These new expanded range membranes provide a solute removal profile more like that of the native kidney than currently available membranes when used in conventional haemodialysis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.